摘要
目的:观察多索茶碱与噻托溴铵粉治疗慢性阻塞性肺疾病患者的临床效果及不良反应。方法:选取德兴市中医院2017年1月-2019年12月收治的96例慢性阻塞性肺疾病患者为研究对象,将其随机分为研究组与对照组,各48例。两组患者入院后均给予基础治疗,对照组在此基础上给予多索茶碱治疗,研究组在对照组基础上给予噻托溴铵粉治疗。观察两组患者治疗后临床效果、肺功能、炎症因子及不良反应发生情况。结果:研究组临床总有效率(91.67%)高于对照组(70.83%)(P<0.05)。两组治疗后FEV;、FVC、FEV;/FVC%均高于本组治疗前(P<0.05);治疗后,研究组上述各指标均高于对照组(P<0.05)。两组治疗后血清IL-6、hs-CRP水平均低于本组治疗前(P<0.05);治疗后,研究组上述各指标水平均低于对照组(P<0.05)。研究组不良反应发生率(4.17%)低于对照组(27.08%)(P<0.05)。结论:多索茶碱与噻托溴铵粉联合应用可提高慢性阻塞性肺疾病患者临床疗效,改善肺功能及炎症反应,且安全性较高,值得临床广泛推广并应用。
Objective:To observe the clinical effects and adverse reactions of Doxofylline and Tiotropium Bromide Powder in the treatment of patients with chronic obstructive pulmonary disease.Method:A total of 96 patients with chronic obstructive pulmonary disease admitted to Dexing Hospital of Traditional Chinese Medicine from January 2017 to December 2019 were selected as the research objects,and they were randomly divided into the study group and the control group,with 48 cases in each group.Both groups were given basic treatment after admission,the control group was given Doxofylline treatment on this basis,and the study group was given Tiotropium Bromide Powder treatment on the basis of the control group.The clinical efficacy,lung function,inflammatory factors and adverse reactions of the two groups were observed after treatment.Result:The total clinical effective rate of the study group (91.67%) was higher than that of the control group (70.83%) (P<0.05).After treatment,FEV;,FVC,and FEV;/FVC% in the two groups were higher than those before treatment (P<0.05);after treatment,the above indexes in the study group were higher than those in the control group (P<0.05).After treatment,the levels of serum IL-6 and hs-CRP in the two groups were lower than those before treatment (P<0.05);after treatment,the above indexes in the study group were lower than those in the control group (P<0.05).The incidence of adverse reactions in the study group (4.17%) was lower than that of the control group (27.08%) (P<0.05).Conclusion:The combined application of Doxofylline and Tiotropium Bromide Powder can improve the clinical efficacy of patients with chronic obstructive pulmonary disease,improve lung function and inflammatory response,and has high safety,it is worthy of clinical widespread promotion and application.
作者
鲍国明
程继芳
余丽萍
BAO Guoming;CHENG Jifang;YU Liping(Dexing Hospital of Traditional Chinese Medicine,Jiangxi Province,Dexing 334200,China;不详)
出处
《中国医学创新》
CAS
2022年第6期64-68,共5页
Medical Innovation of China
关键词
慢阻肺
多索茶碱
噻托溴铵粉
不良反应
Chronic obstructive pulmonary disease
Doxofylline
Tiotropium Bromide Powder
Adverse reactions